查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
流感治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1180662

流感治療的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Influenza Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

由於流感流行的蔓延、對治療藥物的需求增加以及政府在意識和治療方面的舉措將促進市場增長，預計全球流感治療市場在預測期內將顯著增長。

本報告提供全球流感治療市場相關調查分析，提供市場趨勢，競爭分析，市場動態，各市場區隔·各地區的市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 流感治療市場:競爭分析

  • 主要的流感治療市場供應商的市場定位
  • 流感治療市場供應商採用的策略
  • 主要的產業策略
  • 階層分析:2021年對2030年

第4章 流感治療市場:常量分析和市場動態

  • 簡介
  • 全球流感治療市場價值(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析

第5章 流感治療市場:不同治療(2020年～2030年)

  • 市場概要
  • 成長·收益分析:2021年對2030年
  • 市場明細
    • 疫苗
    • 藥物

第6章 北美的流感治療市場(2020年～2030年)

  • 市場概要
  • 不同治療(2020年～2030年)
  • 各地區(2020年～2030年)
    • 北美

第7章 英國·EU的流感治療市場(2020年～2030年)

  • 市場概要
  • 不同治療(2020年～2030年)
  • 各地區(2020年～2030年)
    • 英國·EU

第8章 亞太地區的流感治療市場(2020年～2030年)

  • 市場概要
  • 不同治療(2020年～2030年)
  • 各地區(2020年～2030年)
    • 亞太地區

第9章 南美的流感治療市場(2020年～2030年)

  • 市場概要
  • 不同治療(2020年～2030年)
  • 各地區(2020年～2030年)
    • 南美

第10章 中東·非洲的流感治療市場(2020年～2030年)

  • 市場概要
  • 不同治療(2020年～2030年)
  • 各地區(2020年～2030年)
    • 中東·非洲

第11章 企業簡介

  • Abbott Laboratories
  • Astrazeneca PLC
  • Biocryst Pharmaceuticals, Inc.
  • Chiron Corporation
  • CSL Limited
  • Daiichi Sankyo Co., Ltd.
  • Glaxosmithkline PLC
  • Mitsubishi Tanabe Pharma Corporation
  • Nanotherapeutics Inc.
  • Protein Sciences Corporation
  • Roche Holding AG
  • Sanofi SA
  • Shionogi & Co., Ltd.
  • Sinovac Biotech Ltd.
Product Code: 137539-08-22

Global influenza therapeutics market is anticipated to grow significantly during forecast period due to growing prevalence of influenza, increasing demand for treatment medication, government initiatives in awareness and treatment would drive the growth of influenza therapeutics market globally.

The report titled "Influenza Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall influenza therapeutics market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on technology and different geographical regions.

Market size and forecast for these regional and country level markets are presented in this study for the period 2020-2030. Market growth rates for the forecast period 2022-2030 are also included in this report, considering 2021 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global influenza therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global influenza therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global Influenza therapeutics market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global influenza therapeutics market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors.

Influenza is an acute respiratory disease caused by influenza type A, B or C viruses infection, preventable by vaccination or chemoprophylaxis and is treatable by specific antiviral drugs. The World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3-5 million severe cases and between 250,000- 500,000 deaths. Currently, influenza vaccines (also known as flu shots or jabs) dominating the global influenza market because government initiative for vaccination is prime factor that driving the growth of influenza vaccine market globally; The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk. CDC recommended oral oseltamivir (Tamiflu), inhaled zanamivir (Relenza), and intravenous peramivir (Rapivab) antiviral medications for the treatment; and trivalent- quadrivalent vaccines for the prevention of influenza, these all factors assisting growth of influenza market globally.

The World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3-5 million severe cases and between 250,000 and 500,000 deaths occurs due to influenza infection. It is observed that, currently North America followed by Europe dominating the global influenza market because government initiative such as Centers for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly influenza vaccination for nearly all people over the age of six months, especially those at high risk are primarily driving the growth of influenza market in these region. Also some factors such as growing incidence of infectious diseases, higher healthcare awareness and increase in aging population are fueling the market growth in developed regions. On the other hand, Asia Pacific expected to grow at the highest CAGR during forecast period due to the higher number of targeted population, rising healthcare awareness and government initiatives in prevention of infectious disease would assist the market growth during forecast period in Asia Pacific region.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Influenza Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Influenza Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Therapy

Vaccines

Trivalent

Quadrivalent

Drugs

Zanamivir

Oseltamivir

Peramivir

Other

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Influenza Therapeutics market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Influenza Therapeutics market?

Which is the largest regional market for Influenza Therapeutics market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Influenza Therapeutics market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Influenza Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Influenza Therapeutics Market
  • 2.2. Global Influenza Therapeutics Market, By Therapy, 2021 (US$ Million)
  • 2.3. Global Influenza Therapeutics Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Influenza Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Influenza Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Influenza Therapeutics Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Influenza Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Influenza Therapeutics Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Vaccines
      • 5.3.1.1. Trivalent
      • 5.3.1.2. Quadrivalent
    • 5.3.2. Drugs
      • 5.3.2.1. Zanamivir
      • 5.3.2.2. Oseltamivir
      • 5.3.2.3. Peramivir
      • 5.3.2.4. Other

6. North America Influenza Therapeutics Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
  • 6.3.Influenza Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

7. UK and European Union Influenza Therapeutics Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
  • 7.3.Influenza Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

8. Asia Pacific Influenza Therapeutics Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
  • 8.3.Influenza Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

9. Latin America Influenza Therapeutics Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
  • 9.3.Influenza Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

10. Middle East and Africa Influenza Therapeutics Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
  • 10.3.Influenza Therapeutics Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Influenza Therapeutics Market: By Therapy, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. Abbott Laboratories
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Astrazeneca PLC
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Biocryst Pharmaceuticals, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Chiron Corporation
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. CSL Limited
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Daiichi Sankyo Co., Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Glaxosmithkline PLC
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Mitsubishi Tanabe Pharma Corporation
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Nanotherapeutics Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Protein Sciences Corporation
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. Roche Holding AG
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. Sanofi SA
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Shionogi & Co., Ltd.
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Sinovac Biotech Ltd.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 2 Global Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 3 Global Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 4 North America Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 5 North America Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 6 North America Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 7 U.S. Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 8 U.S. Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 9 U.S. Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 10 Canada Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 11 Canada Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 12 Canada Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 13 Rest of North America Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 14 Rest of North America Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 15 Rest of North America Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 16 UK and European Union Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 17 UK and European Union Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 18 UK and European Union Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 19 UK Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 20 UK Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 21 UK Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 22 Germany Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 23 Germany Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 24 Germany Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 25 Spain Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 26 Spain Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 27 Spain Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 28 Italy Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 29 Italy Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 30 Italy Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 31 France Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 32 France Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 33 France Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 34 Rest of Europe Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 35 Rest of Europe Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 36 Rest of Europe Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 37 Asia Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 38 Asia Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 39 Asia Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 40 China Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 41 China Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 42 China Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 43 Japan Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 44 Japan Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 45 Japan Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 46 India Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 47 India Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 48 India Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 49 Australia Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 50 Australia Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 51 Australia Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 52 South Korea Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 53 South Korea Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 54 South Korea Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 55 Latin America Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 56 Latin America Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 57 Latin America Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 58 Brazil Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 59 Brazil Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 60 Brazil Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 61 Mexico Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 62 Mexico Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 63 Mexico Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 64 Rest of Latin America Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 65 Rest of Latin America Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 66 Rest of Latin America Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 67 Middle East and Africa Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 68 Middle East and Africa Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 69 Middle East and Africa Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 70 GCC Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 71 GCC Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 72 GCC Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 73 Africa Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 74 Africa Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 75 Africa Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)
  • TABLE 76 Rest of Middle East and Africa Influenza Therapeutics Market By Therapy, 2020-2030, USD (Million)
  • TABLE 77 Rest of Middle East and Africa Influenza Therapeutics Market By Vaccines, 2020-2030, USD (Million)
  • TABLE 78 Rest of Middle East and Africa Influenza Therapeutics Market By Drugs, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Influenza Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Influenza Therapeutics Market: Quality Assurance
  • FIG. 5 Global Influenza Therapeutics Market, By Therapy, 2021
  • FIG. 6 Global Influenza Therapeutics Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Influenza Therapeutics Market, 2021
  • FIG. 8 Market Positioning of Key Influenza Therapeutics Market Players, 2021
  • FIG. 9 Global Influenza Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Influenza Therapeutics Market, By Therapy, 2021 Vs 2030, %
  • FIG. 11 U.S. Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 18 France Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 20 China Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 22 India Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Influenza Therapeutics Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Influenza Therapeutics Market (US$ Million), 2020 - 2030